Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPADO: NPLD, Paclitaxel, and Lapatinib in HER2+ Early Breast Cancer
NCT01172223Phase 2Completed
- Start
- Sep 2007
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in breast cancer. Primary endpoints: Optimal doses for NPLD, paclitaxel and lapatinib and Pathological response to NPLD, paclitaxel and lapatinib. Started Sep 2007; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01172223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172223.